Atomo Diagnostics (ASX:AT1) FCF Margin % : -40.59% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Atomo Diagnostics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Atomo Diagnostics's Free Cash Flow for the six months ended in Dec. 2024 was A$-0.77 Mil. Atomo Diagnostics's Revenue for the six months ended in Dec. 2024 was A$1.89 Mil. Therefore, Atomo Diagnostics's FCF Margin % for the quarter that ended in Dec. 2024 was -40.59%.

As of today, Atomo Diagnostics's current FCF Yield % is -28.05%.

The historical rank and industry rank for Atomo Diagnostics's FCF Margin % or its related term are showing as below:

ASX:AT1' s FCF Margin % Range Over the Past 10 Years
Min: -418.82 Med: -150.73 Max: -41.45
Current: -88.43

During the past 5 years, the highest FCF Margin % of Atomo Diagnostics was -41.45%. The lowest was -418.82%. And the median was -150.73%.

ASX:AT1's FCF Margin % is ranked worse than
78.88% of 819 companies
in the Medical Devices & Instruments industry
Industry Median: -3.57 vs ASX:AT1: -88.43

Atomo Diagnostics FCF Margin % Historical Data

The historical data trend for Atomo Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atomo Diagnostics FCF Margin % Chart

Atomo Diagnostics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

-418.82

-150.73

-41.45

-245.64

-115.05

Atomo Diagnostics Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial					-205.30	-291.90	-97.97	-130.28	-40.59

Competitive Comparison of Atomo Diagnostics's FCF Margin %

For the Medical Devices subindustry, Atomo Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atomo Diagnostics's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Atomo Diagnostics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Atomo Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Atomo Diagnostics's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-4.702	/	4.087
	=	-115.05 %

Atomo Diagnostics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-0.768	/	1.892
	=	-40.59 %

Atomo Diagnostics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Atomo Diagnostics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Atomo Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atomo Diagnostics Ltd (ASX:AT1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040

Website

https://www.atomodiagnostics.com

Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.

Atomo Diagnostics Headlines

No Headlines